Background Extending hormonal intrauterine system duration will allow users to have less
need for procedures to provide long-term contraception. Objective This study aimed to …

BACKGROUND Consecutive use of the levonorgestrel-releasing intrauterine system (LNG-
IUS) is increasing. However, little is known about factors that predict the bleeding during …

Our objective was to survey the outcome of treatment with levonorgestrel intrauterine system
(Mirena® LNG-IUS) at 6–18 months in a university affiliated tertiary referral hospital in …

BACKGROUND: Because use of intrauterine contraception is now expanding, this article
reports early US clinical experience with the levonorgestrel-releasing intrauterine system …

Abstract Study Objective To assess clinical performance, bleeding pattern, dysmenorrhea,
and satisfaction up to 1 year after placement of 3 types of intrauterine devices …

The objectives of this study were to evaluate the acceptability of the LNG-IUS Mirena®,
when offered as an additional option in a free choice context, and to evaluate the possibility …

Materials and Methods This was a cross-sectional study conducted at the Human
Reproduction Unit, Department of Obstetrics and Gynecology, School of Medicine …

Objective To evaluate the efficacy and safety of a new, low-dose levonorgestrel intrauterine
contraceptive system (LNG-IUS 12) for up to 5 years of use. Study design In this Phase III …

Abstract BACKGROUND The LNG-IUS has increasingly been used for contraception,
treatment of menorrhagia and endometrial protection during hormone replacement therapy …

Materials and Methods Women 18-35 years with regular menses in need of contraception
were randomized to LNG-IUS12 or LNG-IUS16 (12 or 16 μg/day LNG initial in vitro dose …